UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Initial experience of Emicizumab prophylaxis in children with inhibitor positive severe hemophilia A from a single center in India

Pediatric hematology oncology journal, 2021-06, Vol.6 (2), p.97-99

2021

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

Thrombosis and haemostasis, 2021-03, Vol.121 (3), p.351-360

2021

Volltextzugriff (PDF)

Comprehensive evaluation of anti-emicizumab antibodies in acquired hemophilia A: a detailed case study and methodological evaluation

Journal of thrombosis and haemostasis, 2024-10

2024

Volltextzugriff (PDF)

Emicizumab in hemophilia A with inhibitors: clinical and economic impact of its use in a Cuban patient

Aboutopen, 2022-09, Vol.9, p.83-86

2022

Volltextzugriff (PDF)

Bleeding rate reduction in children with hemophilia A and inhibitors treated with emicizumab in the real-world clinical setting

Voprosy gematologii/onkologii i immunopatologii v pediatrii, 2022-03, Vol.21 (1), p.66-71

2022

Volltextzugriff (PDF)

L’ère des nanocorps et anticorps thérapeutiques en hémostase

Revue francophone des laboratoires, 2024-03, Vol.2024 (561), p.58-64

2024

Volltextzugriff (PDF)

Emicizumab in the treatment of hemophilia A

Acta stomatologica Naissi, 2020, Vol.36 (81), p.2007-2010

2020

Volltextzugriff (PDF)

Combination of emicizumab and factor VIII has no additive effects after reaching normal coagulation levels

Journal of thrombosis and haemostasis, 2021-02, Vol.19 (2), p.597-597

2021

Volltextzugriff (PDF)

Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-01, Vol.27 (1), p.90-99

2021

Volltextzugriff (PDF)

Emicizumab e inmunotolerancia en paciente con hemofilia A e inhibidores:: reporte de caso en Ecuador

Hematología (En línea), 2022, Vol.26 (2), p.1-5

2022

Volltextzugriff (PDF)

Single centre experience of the use of emicizumab in previously untreated and minimally treated patients under 18 months of age

Pediatric blood & cancer, 2024-06, Vol.71 (6), p.e30941-n/a

2024

Volltextzugriff (PDF)

Management of multiple myeloma in a patient with haemophilia with concurrent emicizumab – case report

Journal of Haemophilia Practice, 2021-12, Vol.8 (1), p.136-140

2021

Volltextzugriff (PDF)

Low-dose emicizumab for more equitable access to prophylaxis in resource limited countries

Haemophilia : the official journal of the World Federation of Hemophilia, 2024-05, Vol.30 (3), p.575-576

2024

Volltextzugriff (PDF)

Bispecific antibody characterization by a combination of intact and site-specific/chain-specific LC/MS techniques

Talanta (Oxford), 2022-01, Vol.236, p.122836-122836, Article 122836

2022

Volltextzugriff (PDF)

Hemophilia treatment innovation: 50 years of progress and more to come

Journal of thrombosis and haemostasis, 2023-03, Vol.21 (3), p.403-412

Mannucci, Pier Mannuccio

2023

Volltextzugriff (PDF)

A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A

Journal of thrombosis and haemostasis, 2023-03, Vol.21 (3), p.534-545

2023

Volltextzugriff (PDF)

Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2020-01, Vol.26 (1), p.41-46

2020

Volltextzugriff (PDF)

Comparison of bypassing agents in patients on emicizumab using global hemostasis assays

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-01, Vol.27 (1), p.164-172

2021

Volltextzugriff (PDF)

Efficacy of emicizumab therapy in two adult patients with type 3 von Willebrand disease

Blood coagulation & fibrinolysis, 2024-06, Vol.35 (4), p.206-208

2024

Volltextzugriff (PDF)

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays

Thrombosis and haemostasis, 2019-07, Vol.119 (7), p.1084-1093

2019

Volltextzugriff (PDF)

Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti‐factor IXa/factor X bispecific antibody emicizumab

Journal of thrombosis and haemostasis, 2018-06, Vol.16 (6), p.1078-1088

2018

Volltextzugriff (PDF)

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A

Thrombosis and haemostasis, 2020-10, Vol.120 (10), p.1357-1370

2020

Volltextzugriff (PDF)

Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys

Blood reviews, 2021-09, Vol.49, p.100828-100828, Article 100828

2021

Volltextzugriff (PDF)

Emicizumab reduces re‐hospitalization for bleeding in acquired haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-07, Vol.27 (4), p.e585-e588

2021

Volltextzugriff (PDF)

Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients

Journal of thrombosis and haemostasis, 2024-04, Vol.22 (4), p.1024-1030

2024

Volltextzugriff (PDF)

1 – 25 von 370

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(345)
Mit Volltextzugriff
(288)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Emicizumab
(360)
Science & Technology
(301)
Life Sciences & Biomedicine
(299)
Hematology
(230)
Hemophilia
(190)
Humans
(141)
Hemophilia A
(128)
Prophylaxis
(113)
Hemophilia A - Drug Therapy
(108)
Factor Viii
(79)
Patients
(74)
Monoclonal Antibodies
(71)
Antibodies, Bispecific - Therapeutic Use
(69)
Cardiovascular System & Cardiology
(69)
Coagulation Factors
(69)
Peripheral Vascular Disease
(69)
Haemophilia A
(66)
Bleeding
(64)
Disease Prevention
(52)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(48)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Initial experience of Emicizumab prophylaxis in children with inhibitor positive severe hemophilia A from a single center in India

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

Comprehensive evaluation of anti-emicizumab antibodies in acquired hemophilia A: a detailed case study and methodological evaluation

Emicizumab in hemophilia A with inhibitors: clinical and economic impact of its use in a Cuban patient

Bleeding rate reduction in children with hemophilia A and inhibitors treated with emicizumab in the real-world clinical setting

L’ère des nanocorps et anticorps thérapeutiques en hémostase

Emicizumab in the treatment of hemophilia A

Combination of emicizumab and factor VIII has no additive effects after reaching normal coagulation levels

Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US

Emicizumab e inmunotolerancia en paciente con hemofilia A e inhibidores:: reporte de caso en Ecuador

Single centre experience of the use of emicizumab in previously untreated and minimally treated patients under 18 months of age

Management of multiple myeloma in a patient with haemophilia with concurrent emicizumab – case report

Low-dose emicizumab for more equitable access to prophylaxis in resource limited countries

Bispecific antibody characterization by a combination of intact and site-specific/chain-specific LC/MS techniques

Hemophilia treatment innovation: 50 years of progress and more to come

A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A

Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors

Comparison of bypassing agents in patients on emicizumab using global hemostasis assays

Efficacy of emicizumab therapy in two adult patients with type 3 von Willebrand disease

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays

Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti‐factor IXa/factor X bispecific antibody emicizumab

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A

Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys

Emicizumab reduces re‐hospitalization for bleeding in acquired haemophilia A

Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients

Suchergebnisse filtern